Hang Thuy Nguyen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hang Thuy Nguyen has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Thang Thanh Phan
The Laboratory D Unit, Clinical Cancer Center, Cho Ray Hospital, 201B Nguyen Chi Thanh Street, Dist. 5, Ho Chi Minh City, 700000, Vietnam
3 shared publications Hang Thuy Nguyen
Pathology Department, Cho Ray Hospital, Ho Chi Minh City, Vietnam
2 shared publicationsToan Trong Ho
Laboratory D Unit, Clinical Cancer Center, Cho Ray Hospital, Ho Chi Minh City, Vietnam,
2 shared publicationsAnh Ngoc Van Nguyen
Cho Ray Hosp, Lab Unit D, Ho Chi Minh City, Vietnam
1 shared publicationBinh Thanh Mai
Cho Ray Hosp, Lab Unit D, Ho Chi Minh City, Vietnam
1 shared publicationC. Hoang Khac
Cho Ray Hospital, Urology and Kidney Transplantation Department, Ho Chi Minh, Vietnam
1 shared publication
Latest Publications
- 15 April 2023
- Published by University of Economics and Finance in Journal of Development and Integration
- No. 69
The effects of informal sector competition on innovative activities of firms
This study investigates the effects of informal sector competition on innovative activities of firms using a global context. The research results using Probit regression for a sample containing more than 97,000 observations in 119 countries suggest that informal sector competition has a positive impact on firm innovation. The finding is consistent when using alternatives measures of innovation and informal sector competition. In addition, the positive association between competition from informal sector and innovation is confirmed when using various alternative econometric techniques.
- 15 April 2023
- Published by University of Economics and Finance in Journal of Development and Integration
- No. 69
The effects of informal sector competition on innovative activities of firms
This study investigates the effects of informal sector competition on innovative activities of firms using a global context. The research results using Probit regression for a sample containing more than 97,000 observations in 119 countries suggest that informal sector competition has a positive impact on firm innovation. The finding is consistent when using alternatives measures of innovation and informal sector competition. In addition, the positive association between competition from informal sector and innovation is confirmed when using various alternative econometric techniques.
- Open Access
- 18 February 2022
- Published by Elsevier in Kidney International Reports
- Vol. 7 (2) , S342-S343
POS-800 OUTCOMES OF DECEASED DONOR KIDNEY TRANSPLANTATION AT CHO RAY HOSPITAL, VIETNAM
- 18 February 2022
- Published by Elsevier in Kidney International Reports
- Vol. 7 (2) , S342-S343
Open AccessPOS-800 OUTCOMES OF DECEASED DONOR KIDNEY TRANSPLANTATION AT CHO RAY HOSPITAL, VIETNAM
- Open Access
- 1 November 2018
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 11, 423-430
The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small-cell lung cancer patients treated with EGFR TKI
Purpose: To identify and clarify the roles of inflammatory markers in prognosis for advanced non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitor (TKI). Patients and methods: One hundred and twelve adenocarcinoma, clinical stage IV, NSCLC patients with either EGFR exon 19 deletion (E19del) or EGFR exon 21 L858R substitution mutation (L858R) were selected for this study. The blood cell count at different stages of treatment was used to calculate the inflammatory markers. The Kaplan–Meier statistics and Cox regression model were used to test the differences of progression-free survival (PFS) between groups by the optimal cutoff point of biomarkers. Results: The median values of white blood cell (WBC), neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR) and platelet to lymphocyte ratio (PLR) in NSCLC patients tended to be reduced after 3 months treated with EGFR TKI and increased conversely when the disease develops progression (PPP3cm) and the high level of pretreatment NLR were associated with the shortening of PFS (HR=2.24, 95% CI: 1.04–4.83, P=0.039 and HR=2.67, 95% CI: 1.41–5.03, P=0.006, respectively). Multivariate analysis has shown that the elevated NLR is an independent prognostic marker for worse PFS of NSCLC patients treated with EGFR TKI (HR=2.15, 95% CI: 1.15–3.99, P=0.016). Conclusion: NLR and MLR are valuable markers in response evaluation for NSCLC patients treated with EGFR TKI. The elevated NLR is also an independent prognostic factor for worse survival.
- 1 November 2018
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 11, 423-430
Open AccessThe prognostic impact of neutrophil to lymphocyte ratio in advanced non-small-cell lung cancer patients treated with EGFR TKI
Purpose: To identify and clarify the roles of inflammatory markers in prognosis for advanced non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitor (TKI). Patients and methods: One hundred and twelve adenocarcinoma, clinical stage IV, NSCLC patients with either EGFR exon 19 deletion (E19del) or EGFR exon 21 L858R substitution mutation (L858R) were selected for this study. The blood cell count at different stages of treatment was used to calculate the inflammatory markers. The Kaplan–Meier statistics and Cox regression model were used to test the differences of progression-free survival (PFS) between groups by the optimal cutoff point of biomarkers. Results: The median values of white blood cell (WBC), neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR) and platelet to lymphocyte ratio (PLR) in NSCLC patients tended to be reduced after 3 months treated with EGFR TKI and increased conversely when the disease develops progression (PPP3cm) and the high level of pretreatment NLR were associated with the shortening of PFS (HR=2.24, 95% CI: 1.04–4.83, P=0.039 and HR=2.67, 95% CI: 1.41–5.03, P=0.006, respectively). Multivariate analysis has shown that the elevated NLR is an independent prognostic marker for worse PFS of NSCLC patients treated with EGFR TKI (HR=2.15, 95% CI: 1.15–3.99, P=0.016). Conclusion: NLR and MLR are valuable markers in response evaluation for NSCLC patients treated with EGFR TKI. The elevated NLR is also an independent prognostic factor for worse survival.
- 1 January 2018
- Published by Scitechnol Biosoft Pvt. Ltd. in Australasian Medical Journal
- Vol. 11 (4) , 231-236
Neutrophil to lymphocyte with monocyte to lymphocyte ratio and white blood cell count in prediction of lung cancer
- 1 January 2018
- Published by Scitechnol Biosoft Pvt. Ltd. in Australasian Medical Journal
- Vol. 11 (4) , 231-236
Neutrophil to lymphocyte with monocyte to lymphocyte ratio and white blood cell count in prediction of lung cancer
- 22 November 2017
- Published by Elsevier in Annals of Oncology
- Vol. 28 (suppl_10) , x141-x142
The role of plasma epidermal growth factor receptor mutations test in non-small cell lung cancer
Background: Detecting epidermal growth factor receptor (EGFR) mutated in NSCLC patients by plasma samples (ctDNA) is a non-invasive method, which has demonstrated many substantial benefits in clinical practice. In this study, we evaluated the possibility of detecting EGFR mutations in plasma of stage IIIB-IV NSCLC patients, and monitoring the genetic changes of mutations in the course of treatment.
- 22 November 2017
- Published by Elsevier in Annals of Oncology
- Vol. 28 (suppl_10) , x141-x142
The role of plasma epidermal growth factor receptor mutations test in non-small cell lung cancer
Background: Detecting epidermal growth factor receptor (EGFR) mutated in NSCLC patients by plasma samples (ctDNA) is a non-invasive method, which has demonstrated many substantial benefits in clinical practice. In this study, we evaluated the possibility of detecting EGFR mutations in plasma of stage IIIB-IV NSCLC patients, and monitoring the genetic changes of mutations in the course of treatment.